Related references
Note: Only part of the references are listed.Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation
Wenxing Gu et al.
JOURNAL OF CONTROLLED RELEASE (2021)
In situ activation of STING pathway with polymeric SN38 for cancer chemoimmunotherapy
Jiayu Zhao et al.
BIOMATERIALS (2021)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Cystine proportion regulates fate of polypeptide nanogel as nanocarrier for chemotherapeutics
Xiangru Feng et al.
SCIENCE CHINA-CHEMISTRY (2021)
Albumin-binding prodrugs via reversible iminoboronate forming nanoparticles for cancer drug delivery
Lingqiao Hao et al.
JOURNAL OF CONTROLLED RELEASE (2021)
Sequentially stimuli-responsive anticancer nanomedicines
Lingyu Wei et al.
NANOMEDICINE (2021)
X-ray-responsive polypeptide nanogel for concurrent chemoradiotherapy
Juan Wang et al.
JOURNAL OF CONTROLLED RELEASE (2021)
Design, Synthesis, and Biological Evaluation of HSP90 Inhibitor-SN38 Conjugates for Targeted Drug Accumulation
Shulei Zhu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Controlled loading of albumin-drug conjugates ex vivo for enhanced drug delivery and antitumor efficacy
Xinquan Liu et al.
JOURNAL OF CONTROLLED RELEASE (2020)
In vivo synthesis of triple-loaded albumin conjugate for efficient targeted cancer chemotherapy
Remi Chatre et al.
JOURNAL OF CONTROLLED RELEASE (2020)
KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated drugs
Huiqin Liu et al.
JOURNAL OF CONTROLLED RELEASE (2019)
Novel auristatin E-based albumin-binding prodrugs with superior anticancer efficacy in vivo compared to the parent compound
Lara Pes et al.
JOURNAL OF CONTROLLED RELEASE (2019)
Extended scaffold glucuronides: en route to the universal synthesis of O-aryl glucuronide prodrugs
Raoul Walther et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2019)
Redox-responsive dual chemophotothermal therapeutic nanomedicine for imaging-guided combinational therapy
Fei Yu et al.
JOURNAL OF MATERIALS CHEMISTRY B (2018)
A beta-glucuronidase-responsive albumin-binding prodrug programmed for the double release of monomethyl auristatin E
Brigitte Renoux et al.
MEDCHEMCOMM (2018)
Exploring the Applicability of Nano- Poration for Remote Control in Smart Drug Delivery Systems
Agnese Denzi et al.
JOURNAL OF MEMBRANE BIOLOGY (2017)
Targeting the tumour microenvironment with an enzyme-responsive drug delivery system for the efficient therapy of breast and pancreatic cancers
Brigitte Renoux et al.
CHEMICAL SCIENCE (2017)
Strategies for Preparing Albumin-based Nanoparticles for Multifunctional Bioimaging and Drug Delivery
Fei-Fei An et al.
THERANOSTICS (2017)
1461TiPMULTICENTER PHASE 3 STUDY OF EFFICACY AND SAFETY OF ALDOXORUBICIN VERSUS INVESTIGATOR'S CHOICE FOR RELAPSED/REFRACTORY SOFT TISSUE SARCOMAS
S.P. Chawla et al.
ANNALS OF ONCOLOGY (2017)
Ligand-Targeted Drug Delivery
Madduri Srinivasarao et al.
CHEMICAL REVIEWS (2017)
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-Drug Conjugate for the Treatment of Diverse Epithelial Cancers: Safety and Pharmacokinetics
Allyson J. Ocean et al.
CANCER (2017)
Albumin-binding caspase-cleavable prodrug that is selectively activated in radiation exposed local tumor
Seung Woo Chung et al.
BIOMATERIALS (2016)
Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy
Zhibo Liu et al.
CHEMICAL SOCIETY REVIEWS (2016)
Antibody- Drug Conjugates: An Emerging Concept in Cancer Therapy
Ravi V. J. Chari et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
Albumin-based nanoparticles as potential controlled release drug delivery systems
Ahmed O. Elzoghby et al.
JOURNAL OF CONTROLLED RELEASE (2012)
Synthesis and Antitumor Efficacy of a β-Glucuronidase-Responsive Albumin-Binding Prodrug of Doxorubicin
Thibaut Legigan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect
Yasuhiro Matsumura
ADVANCED DRUG DELIVERY REVIEWS (2011)
Optimization of an Albumin-Binding Prodrug of Doxorubicin That Is Cleaved by Prostate-Specific Antigen
Bakheet Elsadek et al.
ACS MEDICINAL CHEMISTRY LETTERS (2010)
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Felix Kratz
JOURNAL OF CONTROLLED RELEASE (2008)
Nanoparticle albumin bound (nab) technology: targeting tumors through the endothelial gp60 receptor and SPARC
N. Desai
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2007)
Albumin-binding prodrugs of camptothecin and doxorubicin with an ala-leu-ala-leu-linker that are cleaved by cathepsin B: Synthesis and antitumor efficacy
Bjoern Schmid et al.
BIOCONJUGATE CHEMISTRY (2007)
Topoisomerase I inhibitors: camptothecins and beyond
Yves Pommier
NATURE REVIEWS CANCER (2006)
Enhanced therapeutic efficacy formulation of SN-38 against of a novel liposome-based human tumor models in SCID mice
S Lei et al.
ANTI-CANCER DRUGS (2004)
Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives.: Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound
F Kratz et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Synthesis and cytotoxic activity of a glucuronylated prodrug of nornitrogen mustard
S Papot et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2000)
Share Paper
